A Phase 2 Study of Raludotatug Deruxtecan in People With Advanced Solid Tumors

Full Title

REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants with Advanced/Metastatic Solid Tumors

Purpose

Researchers want to see how well raludotatug deruxtecan (R-DXd) works against advanced solid tumors. The people in this study have the following cancers, which have spread despite treatment:

• Endometrial cancer
• Cervical cancer
• Ovarian cancer
• Urothelial cancer (like bladder cancer)
• Clear cell renal cell carcinoma (kidney cancer)

R-DXd is a type of drug called an antibody-drug conjugate. The antibody binds to a protein on cancer cells called CDH6. The linked drug enters these cells and kills them, with reduced risk of harming other cells. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have endometrial, cervical, ovarian, bladder, or kidney cancer that spread and cannot be successfully treated with other therapies.
• Have recovered from the serious side effects of previous treatments before getting the study therapy.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Gopakumar Iyer’s office at 646-888-4737.